7 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Showing 7 of 7 clinical reviews.
Evolocumab (Repatha) carries an FDA-approved indication for reducing cardiovascular events in established ASCVD. Learn the dosing protocol, FOURIER trial evidence, guideline recommendations, and when prescribing may extend beyond the label.
A clinical evidence summary of evolocumab (Repatha) for secondary prevention in atherosclerotic cardiovascular disease (ASCVD), including FOURIER trial data, guideline recommendations, dosing, and safety.
Evolocumab (Repatha) is FDA-approved for heterozygous and homozygous familial hypercholesterolemia. Learn about dosing, monitoring protocols, trial data from FOURIER and RUTHERFORD-2, and guideline recommendations.
A clinician-reviewed guide to evolocumab (Repatha) in ASCVD secondary prevention: FDA-approved vs. Off-label context, FOURIER trial data, dosing protocols, LDL-C targets, and required monitoring.
A physician-reviewed evidence summary covering evolocumab (Repatha) for familial hypercholesterolemia, including FDA-approved indications, off-label use, trial data, dosing, and guideline recommendations.
A clinical review of evolocumab (Repatha) for familial hypercholesterolemia, including FDA approval status, off-label contexts, dosing protocols, trial evidence, and physician guidance.
Evolocumab (Repatha) is FDA-approved for adults with primary hyperlipidemia and established ASCVD, but its use in pediatric FH and certain FH subtypes is technically off-label. This guide covers the evidence base, GRADE ratings, dosing, risks, and how clinicians weigh the trade-offs.